Previous 10 | Next 10 |
2023-03-08 03:27:02 ET Summary HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution. The boom-bust nature of biotech stocks may not be suitable for a steady managed distribution strategy as it unde...
2023-03-05 07:56:14 ET Summary The HQH fund aims to provide high total returns through investments in the healthcare industry. HQH has a high allocation to risky biotech stocks and private investments. The fund pays a 2% of NAV quarterly distribution. However, HQH has under-earned...
Tekla Life Sciences ( NYSE: HQL ) declares $0.33/share quarterly dividend , 6.5% increase from prior dividend of $0.31. Forward yield 9.1% Payable March 31; for shareholders of record Feb. 27; ex-div Feb. 24. See HQL Dividend Scorecard, Yield Chart, & Dividen...
Summary PIMCO's Corporate & Income Opportunity Fund is hot. We share comparative data on over 100 big-yield CEFs, including performance, yield, strategy, discount versus premium, z-scores and more. We review four big-yield CEFs from the list (two that may be overheating and two ...
In the same way that the biopharma sector led the overall market lower in early 2022, biotech is already emerging as one of the sectors that is likely to lead the market higher as 2023 gets underway, suggests Nate Pile, editor of Nate's Notes. For further details see: Top Picks 2023- Tekla ...
Summary 2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to let up on strangling inflation into submission while draini...
Summary We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds ("CEFs") and bonds. We dive deeper into three specific attractive big-yield opportunities that also have healthy upside potential. We begin with a special focus on...
Summary For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the broad...
Summary The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH no...
Tekla Life Sciences ( NYSE: HQL ) declares $0.31/share quarterly dividend , -11.4% decrease from prior dividend of $0.35. Forward yield 8.34% Payable Nov. 30; for shareholders of record Nov. 25; ex-div Nov. 23. See HQL Dividend Scorecard, Yield Chart, &am...
News, Short Squeeze, Breakout and More Instantly...
TeklaLife Sciences Investors Company Name:
HQL Stock Symbol:
NYSE Market:
TeklaLife Sciences Investors Website:
2024-08-01 06:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 05:00:37 ET Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and downside!), as well as these funds’ 8%+ dividend payouts. I was reminded of this recently by a ...
PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / abrdn Life Sciences Investors ("HQL") announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024. As of the record date, April 1, 2024, HQL had outstanding 27,350,517 shares of common stock. 87.84% o...